-
2024-511264-89-00
4
2022-04-11
Glioblastoma
-
2024-516504-42-00
5
2022-03-05
Respiratory distress syndrome in preterm infants
-
2024-512174-10-00
5
2021-11-11
metastatic colorectal cancer
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2024-516392-33-00
5
2021-09-17
Patients (18-75 years) with metastatic and/or refractory soft-tissue
s
-
2024-512953-26-00
5
2021-07-06
intermediate-stage hepatocellular carcinoma
-
2024-515229-26-00
5
2021-05-21
eosinophilic esophagitis
-
2023-509863-26-00
11
2021-04-29
Liver cirrhosis
-
2024-514988-25-00
9
2021-03-31
Cancer
-
2024-514992-16-00
9
2021-03-31
Cancer
-
2024-514993-38-00
9
2021-03-31
Cancer
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2024-517300-10-01
5
2020-12-17
Resectable diffuse type gastric and gastroesophageal junction Typ II/I
-
2024-510616-73-00
5
2020-12-16
newly diagnosed WHO grade 2 or 3 glioma
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-504888-16-00
9
2020-10-05
Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-expressi
-
2024-518077-34-00
5
2020-09-30
locally advanced rectal cancer
-
2024-514014-13-00
9
2020-09-02
female and male adult patients with acute myeloid leukemia
-
2023-505737-26-00
5
2020-07-22
Steroid refractory Acute Graft versus host Disease
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2024-514383-61-00
6
2020-07-07
Diarrhoea predominant irritable bowel syndrome
-
2024-514494-21-00
4
2020-05-13
autoimmune encephalitis
-
2024-514892-16-00
6
2020-05-05
Diarrhoea predominant irritable bowel syndrome